Taheri Mohammad, Nemati Shirin, Movafagh Abolfazl, Saberi Mohammad, Mirfakhraie Reza, Eftekharian Mohammad Mahdi, Arsang-Jang Shahram, Rezagholizadeh Amir, Sayad Arezou
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Tehran medical University of Medical Sciences, Tehran, Iran.
Hum Antibodies. 2016 May 20;24(1-2):33-8. doi: 10.3233/HAB-160291.
Multiple sclerosis (MS) as an autoimmune disorder in which the insulating covers of neurons in the Central Nervous System are destructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an immunomodulatory molecule to protect against T cells hyper activation.
In this Case-control study, we compare TRAIL gene expression in peripheral blood between 50 relapse remitting MS patients and 50 healthy controls by TaqMan Real time PCR. All the patients were negative for HLA-DRB1*15 susceptible allele, normal serum vitamin D, responder to Interferon beta. All the health individuals were matched to patients. Also, we tried to find correlation between TRAIL gene expression and clinical characteristics of patients.
No statistically significant difference was found in TRAIL mRNA expression between MS patients and controls (p> 0.05). There was no correlation in the TRAIL expression and age of onset, disease duration and Expanded Disability Status Scale of Kurtzke (EDSS). As IFN-b may have stimulatory effects on immunoregulatory function of TRAIL and all of our patients were treated with interferon beta and were responder, it lead to no significant change in TRAIL expression. We suggest comparing between responders and non-responders should be investigated.
多发性硬化症（MS）是一种自身免疫性疾病，其中中枢神经系统中神经元的绝缘覆盖物被破坏。肿瘤坏死因子相关凋亡诱导配体（TRAIL）是一种免疫调节分子，可防止T细胞过度活化。
在本病例对照研究中，我们通过TaqMan实时PCR比较了50例复发缓解型MS患者和50例健康对照者外周血中TRAIL基因的表达。所有患者的HLA-DRB1*15易感等位基因为阴性，血清维生素D正常，对干扰素β有反应。所有健康个体均与患者匹配。此外，我们试图找出TRAIL基因表达与患者临床特征之间的相关性。
MS患者与对照组之间TRAIL mRNA表达无统计学显著差异（p>0.05）。TRAIL表达与发病年龄、病程和Kurtzke扩展残疾状态量表（EDSS）之间无相关性。由于IFN-β可能对TRAIL的免疫调节功能有刺激作用，且我们所有的患者均接受了干扰素β治疗且有反应，因此TRAIL表达无显著变化。我们建议应研究有反应者与无反应者之间的比较。
